BioSpace News Archive

Syntach AB in Lund, Sweden has been awarded € 2.5 million as a grant and part of blended finance of up to € 17,5 million from the European Innovation Council to support the development of its unique minimally invasive cardiac support system.

Genenta Science S.p.A., a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for solid tumors, including the lead product candidate, Temferon™, announced the closing of its upsized initial public offering of 2.4 million American Depositary Shares at a public offering price of $11.50 per ADS.

Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Amgen and AstraZeneca’s Tezspire™ (tezepelumab-ekko) for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma.

Iovance Biotherapeutics, Inc., a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, announced that on December 16, 2021, the Company approved the grant of inducement stock options covering an aggregate of 107,900 shares of Iovance’s common stock to eleven new non-executive employees.

The U.S. Food and Drug Administration today approved Vyvgart (efgartigimod) for the treatment of generalized myasthenia gravis (gMG) in adults who test positive for the anti-acetylcholine receptor (AChR) antibody.

AstraZeneca and Amgen’s TEZSPIRE (tezepelumab-ekko) has been approved in the US for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma.

bluebird bio, Inc. (Nasdaq: BLUE) today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review the Biologics License Application (BLA) for elivaldogene autotemcel (eli-cel, Lenti-D®), the company’s gene therapy for cerebral adrenoleukodystrophy (CALD) in patients less than 18 years of age.

Arcturus Therapeutics Holdings Inc. announced that the Compensation Committee of the Company’s Board of Directors and the Company’s Board of Directors approved inducement grants of stock options to purchase an aggregate of 13,800 shares of Arcturus’ common stock to three newly-hired employees.

According to Emergen Research, the global bariatric surgery market size was USD 2.41 Billion in 2020 and is expected to reach USD 4.81 Billion in 2028 and register a revenue CAGR of 9.0% during the forecast period, 2021-2028.

According to Emergen Research, the global compound management market size was USD 285.6 Million in 2020 and is expected to reach USD 826.2 Million in 2028 and register a revenue CAGR of 14.1% during the forecast period, 2021-2028.